Patents Assigned to International Institute of Cancer Immunology, Inc.
  • Patent number: 11759509
    Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 19, 2023
    Assignees: Sumitomo Pharma Co., Ltd., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Chiang Jia Li, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
  • Patent number: 11732018
    Abstract: The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: August 22, 2023
    Assignee: International Institute Of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Patent number: 11707512
    Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: July 25, 2023
    Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • Publication number: 20230183316
    Abstract: The present disclosure includes a pharmaceutical composition for treating a cancer in an HLA-A*02:07, HLA-A*03:01, HLA-B*15:01, or HLA-B*27:05-positive subject comprising a WT1-derived cancer antigen peptide or a peptide conjugate containing the peptide.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicants: SUMITOMO PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Masashi GOTO, Natsuko SUGINOBE, Megumi NAKAMURA
  • Patent number: 11555814
    Abstract: Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: January 17, 2023
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Publication number: 20220313770
    Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
    Type: Application
    Filed: June 17, 2022
    Publication date: October 6, 2022
    Applicant: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo SUGIYAMA
  • Patent number: 11413322
    Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: August 16, 2022
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Patent number: 11369656
    Abstract: The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: June 28, 2022
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Publication number: 20220120754
    Abstract: Disclosed is a method for selecting a potential subject with benefiting from a pharmaceutical composition for treating or preventing cancer, comprising: determining the presence or absence of a mutation in tumor protein p53 (TP53) gene and/or BCL6 co-repressor (BCOR) gene by using a sample collected from the subject; and providing an indication that the subject is a potential subject with benefiting from the pharmaceutical composition in the case of TP53 wild type and/or BCOR wild type.
    Type: Application
    Filed: February 27, 2020
    Publication date: April 21, 2022
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Erina YAMAKAWA, Masashi GOTO
  • Publication number: 20220008528
    Abstract: The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1126 killer peptide and/or WT135 helper peptide.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 13, 2022
    Applicants: International Institute of Cancer Immunology, Inc., Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Haruo SUGIYAMA
  • Patent number: 11091531
    Abstract: The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4+ helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4+ T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4+ T-cells, the treatment of cancer, etc.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: August 17, 2021
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki
  • Patent number: 11027003
    Abstract: The present invention provides a WT1-derived HLA-DRB1*0405-binding antigen peptide, a polynucleotide encoding said peptide, a helper T cell inducer comprising said peptide or polynucleotide, and the like. It is related to a partial peptide consisting of 10-25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells, a polynucleotide encoding said peptide, or a helper T cell inducer comprising said peptide or polynucleotide.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 8, 2021
    Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • Publication number: 20210100886
    Abstract: The present disclosure relates to a WT1 peptide having a cysteine residue and including 10 to 12 residues, a peptide conjugate containing the same, and a combination of the WT1 peptide or the peptide conjugate and a WT1 helper peptide.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 8, 2021
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Hitoshi BAN, Yosuke TAKANASHI
  • Patent number: 10947503
    Abstract: Provided is a method for increasing the proportion of memory T cells in a T cell population, said method comprising a step of adding a modulator for the retinoid metabolic pathway and/or a modulator for the retinoic acid signaling system to the T cell population.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: March 16, 2021
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki
  • Publication number: 20200368338
    Abstract: The present disclosure includes a compound of formula (1): wherein cancer antigen peptide A is an MHC class I-restricted peptide consisting of 7 to 30 amino acid residues and containing at least one cysteine residue, wherein the cysteine residue of the cancer antigen peptide A binds to R1 via a disulfide bond; and R1 is hydrogen, a group of formula (2), the group of formula (3), or cancer antigen peptide D, wherein the group of formula 2 is wherein Xa and Yd independently represent a single bond or a divalent peptide group consisting of 1 to 4 amino acid residues, provided that the sum of the number of amino acid residues in Xa and Ya is an integer of 0 to 4, and the cancer antigen peptide B is an MHC class II-restricted peptide consisting of 9 to 30 amino acid residues, wherein the amino group of the N-terminal amino acid of the cancer antigen peptide B binds to Ya in the formula (2), and the carbonyl group of the C-terminal amino acid of the cancer antigen peptide B binds to the hydroxyl group in
    Type: Application
    Filed: December 26, 2018
    Publication date: November 26, 2020
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventors: Hitoshi BAN, Yosuke TAKANASHI
  • Publication number: 20200354405
    Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.
    Type: Application
    Filed: March 31, 2020
    Publication date: November 12, 2020
    Applicants: International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruo SUGIYAMA, Shinji SOGO, Masayoshi SATO, Ryuki KITAMOTO, Yoshihiro GOTO
  • Patent number: 10815288
    Abstract: The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4+ helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4+ T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4+ T-cells, the treatment of cancer, etc.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 27, 2020
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki
  • Patent number: 10759840
    Abstract: The present invention relates to a WT1 peptide which has an amino acid sequence consisting of contiguous amino acids derived from a WT1 protein and induces WT1-specific helper T cells by binding to an MHC class II molecule, a pharmaceutical composition comprising them and the like.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: September 1, 2020
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama
  • Patent number: 10752669
    Abstract: The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4+ helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4+ T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4+ T-cells, the treatment of cancer, etc.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: August 25, 2020
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki
  • Patent number: 10669584
    Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: June 2, 2020
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventor: Haruo Sugiyama